Rivastigmine酒石酸卡巴拉汀,129101-54-

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Rivastigmine tartrate

CAS No. : 129101-54-8

MCE 国际站：Rivastigmine tartrate

产品活性：Rivastigmine tartrate (ENA 713; SDZ-ENA 713) 是一种具有口服活性的，有效的胆碱酯酶 (ChE) 抑制剂，可抑制丁酰胆碱酯酶 (BChE) 和乙酰胆碱酯酶 (AChE)，IC₅₀ 分别为 0.037 μM 和 4.15 μM。Rivastigmine tartrate 可透过血脑屏障 (BBB)。Rivastigmine tartrate 是一种拟副交感神经剂或胆碱能剂，用于研究轻度至中度阿尔茨海默氏型痴呆和帕金森氏病引起的痴呆。

研究领域：Neuronal Signaling

作用靶点：Cholinesterase (ChE)

In Vitro: Rivastigmine tartrate (ENA 713; 1 µM; 24 hours) reduces LPS (2.5 µg/ml)-induced TNF-α and IL-6 by 50% and 46% combined with carbachol (10 µM), respectively and does not cause any significant reduction in pro-inflammatory cytokines .
Rivastigmine tartrate (1 µM), carbachol (10 µM), or a combination of both drugs, does not have a cytotoxic effect on activated cells.

In Vivo: Rivastigmine tartrate (ENA 713; 0.5-2.5 mg/kg; IP; 60 min before the tests) significantly and dose-dependently improved the behavioral impairments caused by Aluminum (HY-B1521).
Rivastigmine (0.5, 1 mg/kg/day; s.c; for 8 days) reduces by about 50% and 60% respectively, the concentration of IL-6 but not those of TNF-α and IL-1β in BALB/c OlaHsd male mice aged 8-9 weeks weighing 200–250 g with acute colitis.
Rivastigmine (1 mg/kg), but not (0.5 mg/kg), partially antagonized colon shrinkage and completely prevented bleeding. Treatment with rivastigmine (0.5 mg/kg) causes little change in these pathological manifestations, but rivastigmine (1 mg/kg) causes a partial restoration of the structure of the crypts and a reduction in sub-mucosal edema and cell infiltration. Rivastigmine (1 mg/kg) causes a 4.7% reduction in body weight at the end of the experiment.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer's Disease Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Parkinson's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  Human Metabolite Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Donepezil Hydrochloride  |  α-NETA  |  TMPyP4 tosylate  |  Galanthamine  |  Garcinol  |  Physostigmine salicylate  |  Scopoletin  |  Rivastigmine  |  Protopine  |  sn-Glycero-3-phosphocholine  |  (-)-Huperzine A  |  Protriptyline hydrochloride  |  Hemicholinium 3  |  Imperatorin  |  Tacrine hydrochloride  |  Tacrine  |  Timosaponin AIII  |  Corynoline  |  Linarin  |  Pyridostigmine bromide  |  Buntanetap  |  Acetylcholinesterase  |  Epiberberine chloride  |  Sinapine  |  Corydaline  |  Cyanidin-3-O-galactoside chloride  |  Isoimperatorin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds